RxDoctor Payments Data

Stephanie Hoatson, MD

Ophthalmology · Orlando, FLNPI 1477940641

Payments from drug & device makers

$2,773in general payments, 2019–2025

Across 79 payments — averaging $35.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bausch & Lomb, A Division Of Bausch Health US, LLC$886
  • AbbVie$483
  • Alcon$329
  • Sun Pharmaceutical Industries Inc.$278
  • Oyster Point Pharma, Inc.$154
  • Rxsight Inc$115
  • plus $528 from 10 others

What the payments were for

  • Travel & lodging$68925%
  • Food & beverage$2,08475%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,773 in reported general payments places this provider in the 55th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$127,446
Medicare patients
477
Services billed
1,028

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine103$148,567
LumiganBimatoprost78$42,254
RocklatanNetarsudil Mesylat/Latanoprost43$37,532
Cyclosporine15$11,363
RhopressaNetarsudil Mesylate15$9,752
CequaCyclosporine13$9,501
Prednisolone Acetate177$6,331
Latanoprost426$5,969
Travoprost19$4,604
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat199$4,285
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$3,045
Brimonidine Tartrate90$3,023
Ketorolac Tromethamine86$2,810
Timolol Maleate109$1,232
Ofloxacin58$822

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$483$190,821181 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$98$47,28458 claims
Sun Pharmaceutical Industries Inc.Cequa$278$9,50113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →